Epoch Investment Partners Inc. Sells 11,816 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Epoch Investment Partners Inc. reduced its stake in Thermo Fisher Scientific by 8.0%, selling 11,816 shares in the first quarter, leaving it with 135,275 shares valued at approximately $67.3 million.
• Several institutional investors have recently increased their positions in Thermo Fisher Scientific, reflecting strong interest in the company, which now has institutional ownership of 89.23%.
• The company reported earnings of $5.36 per share for the last quarter, beating estimates and reflecting a year-over-year revenue growth of 2.9% to $10.86 billion.

Epoch Investment Partners Inc. cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,275 shares of the medical research company's stock after selling 11,816 shares during the period. Epoch Investment Partners Inc.'s holdings in Thermo Fisher Scientific were worth $67,313,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Bernard Wealth Management Corp. bought a new stake in Thermo Fisher Scientific in the 4th quarter worth about $25,000. Ameriflex Group Inc. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $30,000. Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $31,000. IMA Advisory Services Inc. bought a new stake in Thermo Fisher Scientific during the first quarter worth $35,000. Finally, Navigoe LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $37,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,896 shares of company stock worth $13,603,438. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 0.4%

TMO opened at $488.93 on Wednesday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a market cap of $184.63 billion, a PE ratio of 28.28, a price-to-earnings-growth ratio of 2.62 and a beta of 0.74. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a 50 day moving average of $446.71 and a 200 day moving average of $455.47.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. UBS Group raised their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Argus decreased their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating on the stock. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research note on Friday, July 11th. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.